Published January 29, 2018
| Version v1
Dataset
Open
Optimising C2C12 muscle myoblast transfection with polyethylenimine (PEI) or Lipofectamine-2000
Authors/Creators
- 1. Structural Genomics Consortium, University of Oxford
Description
Optimisation of DNA transfection of the C2C12 muscle myoblast cell line, comparing use of polyethylenimine (PEI) and Lipofectamine-2000 with varying treatment conditions.
Notes
Funding Acknowledgment: The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
Files
Optimising_C2C12_transfection_methods_20180129.pdf
Files
(978.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:57550e38e150abeaca200002f539559a
|
978.6 kB | Preview Download |